ArticleJCO oncology advances2025

Maintenance Capecitabine Plus Ramucirumab After First-Line Chemotherapy in Patients With Advanced Esophagogastric Adenocarcinoma: Results From the Randomized PLATFORM Study.

Anderley Gordon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.